Bio-Rad Labs (BIO) Tops Q3 EPS by $1.20

Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $3.00, $1.20 better than the analyst estimate of $1.80. Revenue for the quarter came in at $647.3 million versus the consensus estimate of $570.58 million.

2020 Financial Outlook:

The company currently believes that full-year 2020 year-over-year currency-neutral sales may be up 5.9 to 6.3 percent with an estimated non-GAAP operating margin of 16.0 to 16.5 percent. Management will discuss this outlook in greater detail on the third-quarter 2020 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.

You May Also Be Interested In

• Oracle reports earnings today: AI spending bet faces its toughest test yet
• DA Davidson Reiterates Buy Rating on EVI Industries Inc. (EVI) Following Q4 Results
• American Eagle Outfitters (AEO) PT Lowered to $27 at UBS, Buy Rating Maintained